Safety and Efficacy of Palbociclib (CDK4/6 inhibitor) and Radiotherapy in Metastatic Breast Cancer Patients: Initial Results of a Novel Combination

被引：0
|
作者：
Chowdhary, M. [1 ]
Sen, N. [1 ]
Chowdhary, A. [2 ]
Usha, L. [1 ]
Cobleigh, M. [1 ]
Wang, D. [1 ]
Patel, K. [3 ]
Barry, P. N., Jr. [1 ]
Rao, R. [1 ]
机构：
[1] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[3] Yale Sch Med, New Haven, CT USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2019年 / 105卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2019.06.619
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2002
引用
收藏
页码：E2 / E2
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of palbociclib and radiotherapy in metastatic breast cancer patients: Initial results of a novel combination
    Chowdhary, M.
    Sen, N.
    Chowdhary, A.
    Usha, L.
    Cobleigh, M.
    Patel, K. R.
    Wang, D.
    Barry, P. N.
    Rao, R. D.
    CANCER RESEARCH, 2019, 79 (04)
  • [2] Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination
    Chowdhary, Mudit
    Sen, Neilayan
    Chowdhary, Akansha
    Usha, Lydia
    Cobleigh, Melody A.
    Wang, Dian
    Patel, Kirtesh R.
    Barry, Parul N.
    Rao, Ruta D.
    ADVANCES IN RADIATION ONCOLOGY, 2019, 4 (03) : 453 - 457
  • [3] Palliative Radiotherapy in Metastatic Breast Cancer Patients on CDK4/6 Inhibitors: Safety Analysis
    Ceylan, Furkan
    Mehdiyev, Mirmehdi
    Bilgin, Burak
    Tenekeci, Ates Kutay
    Yalcin, Bulent
    Akinci, M. Bulent
    Dede, Didem Sener
    Sendur, Mehmet Ali Nahit
    Algin, Efnan
    Yucel, Sebnem
    CANCERS, 2025, 17 (03)
  • [4] Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
    van Aken, Evert S. M.
    Beeker, Aart
    Houtenbos, Ilse
    Pos, Floris J.
    Linn, Sabine C.
    Elkhuizen, Paula H. M.
    de Jong, Monique C.
    CANCER REPORTS, 2022, 5 (02)
  • [5] Follicular Lymphoma Response with CDK4/6 Inhibitor(Palbociclib) Utilized in the Setting of Metastatic Breast Cancer
    Ali, Syed S.
    Mertens, Wilson
    BLOOD, 2017, 130
  • [6] Safety of CDK4/6 Inhibitors Combined with Radiotherapy in Patients with Metastatic Breast Cancer: A Review of the Literature
    Franco, Rejane
    Cao, Jeffrey Q.
    Yassa, Michael
    Hijal, Tarek
    CURRENT ONCOLOGY, 2023, 30 (06) : 5485 - 5496
  • [7] Safety and efficacy of concomitant RT and CDK4/6 inhibitors in metastatic breast cancer patients.
    Visani, L.
    Saieva, C.
    Desideri, I.
    Scotti, V.
    Dominici, L.
    Scoccimarro, E.
    Aquilano, M.
    Cerbai, C.
    Palmieri, V. E.
    Maragna, V.
    Becherini, C.
    Bernini, M.
    Sanchez, L.
    Orzalesi, L.
    Nori, J.
    Antonuzzo, L.
    Bianchi, S.
    Meattini, I.
    Livi, L.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S495 - S496
  • [8] The novel potential of palbociclib (CDK4/6 inhibitor) in the treatment of triple-negative breast cancer
    Kashiwagi, Shinichiro
    Asano, Yuka
    Goto, Wataru
    Takada, Koji
    Takashima, Tsutomu
    Morisaki, Tamami
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    Ohira, Masaichi
    CANCER RESEARCH, 2017, 77
  • [9] The novel potential of palbociclib (CDK4/6 inhibitor) in the treatment of triple-negative breast cancer
    Asano, Yuka
    Kashiwagi, Shinichiro
    Goto, Wataru
    Takahashi, Katsuyuki
    Takashima, Tsutomu
    Noda, Satoru
    Onoda, Naoyoshi
    Tomita, Shuhei
    Hirakawa, Kosei
    Ohira, Masaichi
    CANCER RESEARCH, 2017, 77
  • [10] TARGETED COMBINATION THERAPY WITH CDK4/6 INHIBITOR PALBOCICLIB IN AML
    Uras, I.
    Valent, P.
    Sexl, V.
    HAEMATOLOGICA, 2017, 102 : 207 - 208
12345